LD
Clinical Research of Philadelphia Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Liver Disease (MASLD/NAFLD) Program | Metabolic dysfunction-associated steatotic liver disease (MASLD) / Non-alcoholic fatty liver disease (NAFLD) | Various (Typically Phase 2-4) |
| LP(a) Program | Elevated Lipoprotein(a) for prevention of first cardiovascular event | Various (Typically Phase 3) |
| Type 2 Diabetes Program | Type 2 Diabetes Mellitus | Various (Typically Phase 2-4) |
| Women's Health Portfolio | Contraceptives, Endometriosis, Fibroids, Hot Flashes, Overactive bladder, Dispareunia | Various |
| Dermatology/Rheumatology Portfolio | Psoriasis, Dermatitis, Hidradenitis Suppurativa, Rheumatoid Arthritis, Lupus, Fibromyalgia | Various |
| Metabolic Disease Portfolio | Cardiovascular Disease, Obesity, Hypertension, Chronic Kidney Disease (CKD), Rare Disease | Various |
| Neurology Portfolio | Migraines, Alzheimer's Disease | Various |
Leadership Team at Clinical Research of Philadelphia
AV
Aneesh Vaze
Managing Director, Clinical Lead
LU
Liz Usmiani
Non-Clinical Lead
EA
Eugene Andruczyk
Principal Investigator, Board-Certified Obstetrician-Gynecologist
LV
Lolita Vaughan
Principal Investigator, CNRP, CCRC
MT
Michael Tomeo
Principal Investigator, Board-Certified Dermatologist
TM
Taher Modarressi
Principal Investigator, Cardiometabolic Specialist and Board-Certified Endocrinologist
LL
Lawrence Leventhal
Principal Investigator, Board-Certified in Internal Medicine and Rheumatology
HG
Hal Ganzman
Sub-Investigator, Board-Certified Family Medicine Physician
BS
Brian Shaffer
Sub-Investigator, Board-Certified Internal Medicine Physician
JC
Jeehan Choudhary
Clinical Operations Lead